Targeted repression of DNA topoisomerase I by CRISPRi reveals a critical function for it in the Chlamydia trachomatis developmental cycle

Chlamydia trachomatis is an obligate intracellular bacterium that is responsible for the most prevalent bacterial sexually transmitted infections. Changes in DNA topology in this pathogen have been linked to its pathogenicity-associated developmental cycle. Here, evidence is provided that the balanced activity of DNA topoisomerases (Topos) contributes to Chlamydia developmental processes. Utilizing catalytically inactivated Cas12 (dCas12) based-clustered regularly interspaced short palindromic repeats interference (CRISPRi) technology, we demonstrate targeted knockdown of chromosomal topA transcription in C. trachomatis without detected toxicity of dCas12. Repression of topA impaired the growth of C. trachomatis mostly through disruption of its differentiation from a replicative form to an infectious form. Consistent with this, expression of late developmental genes of C. trachomatis was downregulated while early genes maintained their expression. Importantly, the growth defect associated with topA knockdown was rescued by overexpressing topA at an appropriate degree and time, directly linking the growth patterns to the levels of topA expression. Interestingly, topA knockdown had pleiotropic effects on DNA gyrase expression, indicating a potential compensatory mechanism for survival to offset TopA deficiency. C. trachomatis with topA knocked down displayed hypersensitivity to moxifloxacin that targets DNA gyrase in comparison with the wild type. These data underscore the requirement of integrated topoisomerase actions to support the essential development and transcriptional processes of C. trachomatis. Importance We used genetic and chemical tools to demonstrate the relationship of topoisomerase activities and their obligatory role for the chlamydial developmental cycle. Successfully targeting the essential gene topA with a CRISPRi approach, using dCas12, in C. trachomatis indicates that this method will facilitate the characterization of the essential genome. These findings have an important impact on our understanding of the mechanism(s) by which well-balanced topoisomerase activities enable C. trachomatis to adapt to unfavorable growth conditions imposed by antibiotics.

[1]  R. Heinzen,et al.  A Survey of Two-Component Systems in Coxiella burnetii Reveals Redundant Regulatory Schemes and a Requirement for an Atypical PhoBR System in Mammalian Cell Infection , 2023, Journal of bacteriology.

[2]  Ziyu Hua,et al.  Diversity of σ66-Specific Promoters Contributes to Regulation of Developmental Gene Expression in Chlamydia trachomatis , 2023, Journal of bacteriology.

[3]  W. Vollmer,et al.  An NlpC/P60 protein catalyzes a key step in peptidoglycan recycling at the intersection of energy recovery, cell division and immune evasion in the intracellular pathogen Chlamydia trachomatis , 2022, bioRxiv.

[4]  K. Severinov,et al.  Interaction between transcribing RNA polymerase and topoisomerase I prevents R-loop formation in E. coli , 2021, Nature Communications.

[5]  Christopher M. Taylor,et al.  Mycoplasma decontamination in Chlamydia trachomatis culture: a curative approach. , 2021, Pathogens and Disease.

[6]  C. Gross,et al.  Morphological and Transcriptional Responses to CRISPRi Knockdown of Essential Genes in Escherichia coli , 2021, mBio.

[7]  J. Cox,et al.  A Dynamic, Ring-Forming Bactofilin Critical for Maintaining Cell Size in the Obligate Intracellular Bacterium Chlamydia trachomatis , 2021, Infection and immunity.

[8]  S. Ouellette,et al.  CRISPR Interference To Inducibly Repress Gene Expression in Chlamydia trachomatis , 2021, Infection and immunity.

[9]  Qiyao Wang,et al.  Gene Silencing Through CRISPR Interference in Bacteria: Current Advances and Future Prospects , 2021, Frontiers in Microbiology.

[10]  M. Machner,et al.  A multiplex CRISPR interference tool for virulence gene interrogation in Legionella pneumophila , 2021, Communications Biology.

[11]  Y. Tse‐Dinh,et al.  Type IA Topoisomerases as Targets for Infectious Disease Treatments , 2021, Microorganisms.

[12]  P. Shirote,et al.  Fluoroquinolones: Blessings Or Curses. , 2020, Current drug targets.

[13]  J. Cox,et al.  Division without Binary Fission: Cell Division in the FtsZ-Less Chlamydia , 2020, Journal of Bacteriology.

[14]  G. Plano,et al.  Context-Dependent Action of Scc4 Reinforces Control of the Type III Secretion System , 2020, Journal of bacteriology.

[15]  M. Mhlanga,et al.  Arrayed CRISPRi and quantitative imaging describe the morphotypic landscape of essential mycobacterial genes , 2020, bioRxiv.

[16]  W. Nasser,et al.  DNA Supercoiling: an Ancestral Regulator of Gene Expression in Pathogenic Bacteria? , 2019, Computational and structural biotechnology journal.

[17]  S. Ouellette.  Feasibility of a Conditional Knockout System for Chlamydia Based on CRISPR Interference , 2018, Front. Cell. Infect. Microbiol..

[18]  Ziyu Hua,et al.  Novel Detection Strategy To Rapidly Evaluate the Efficacy of Antichlamydial Agents , 2016, Antimicrobial Agents and Chemotherapy.

[19]  C. Dorman,et al.  DNA supercoiling is a fundamental regulatory principle in the control of bacterial gene expression , 2016, Biophysical Reviews.

[20]  J. Cox,et al.  Polarized Cell Division of Chlamydia trachomatis , 2016, PLoS pathogens.

[21]  M. Tan,et al.  Functional analysis of three topoisomerases that regulate DNA supercoiling levels in Chlamydia , 2016, Molecular microbiology.

[22]  K. A. Fields,et al.  Gene Deletion by Fluorescence-Reported Allelic Exchange Mutagenesis in Chlamydia trachomatis , 2016, mBio.

[23]  Patrick Sobetzko,et al.  Chromosomal “Stress-Response” Domains Govern the Spatiotemporal Expression of the Bacterial Virulence Program , 2015, mBio.

[24]  M. Horn,et al.  Chlamydial metabolism revisited: interspecies metabolic variability and developmental stage-specific physiologic activities. , 2014, FEMS microbiology reviews.

[25]  H. Agaisse,et al.  Expression of the Effector Protein IncD in Chlamydia trachomatis Mediates Recruitment of the Lipid Transfer Protein CERT and the Endoplasmic Reticulum-Resident Protein VAPB to the Inclusion Membrane , 2014, Infection and Immunity.

[26]  T. Hackstadt,et al.  Expression and Targeting of Secreted Proteins from Chlamydia trachomatis , 2014, Journal of bacteriology.

[27]  M. Ferrándiz,et al.  The Fluoroquinolone Levofloxacin Triggers the Transcriptional Activation of Iron Transport Genes That Contribute to Cell Death in Streptococcus pneumoniae , 2013, Antimicrobial Agents and Chemotherapy.

[28]  G. Zhong,et al.  Characterization of Chlamydia trachomatis Plasmid-Encoded Open Reading Frames , 2013, Journal of bacteriology.

[29]  T. Hsieh,et al.  New mechanistic and functional insights into DNA topoisomerases. , 2013, Annual review of biochemistry.

[30]  C. Wolz,et al.  Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in Staphylococcus aureus. , 2013, The Journal of antimicrobial chemotherapy.

[31]  T. Hackstadt,et al.  Developmental stage-specific metabolic and transcriptional activity of Chlamydia trachomatis in an axenic medium , 2012, Proceedings of the National Academy of Sciences.

[32]  M. Tan,et al.  The early gene product EUO is a transcriptional repressor that selectively regulates promoters of Chlamydia late genes , 2012, Molecular microbiology.

[33]  M. Tan,et al.  Differential Effects of DNA Supercoiling on Chlamydia Early Promoters Correlate with Expression Patterns in Midcycle , 2012, Journal of bacteriology.

[34]  R. Skilton,et al.  Development of a Transformation System for Chlamydia trachomatis: Restoration of Glycogen Biosynthesis by Acquisition of a Plasmid Shuttle Vector , 2011, PLoS pathogens.

[35]  D. Hughes,et al.  Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness , 2009, PLoS pathogens.

[36]  M. Tan,et al.  DNA Supercoiling-Dependent Gene Regulation in Chlamydia , 2008, Journal of bacteriology.

[37]  W. Solbach,et al.  Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D. , 2007, The Journal of antimicrobial chemotherapy.

[38]  Marcel Geertz,et al.  Homeostatic regulation of supercoiling sensitivity coordinates transcription of the bacterial genome , 2006, EMBO reports.

[39]  Yasser M. Abdelrahman,et al.  The chlamydial developmental cycle. , 2005, FEMS microbiology reviews.

[40]  R. Brunham,et al.  Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine , 2005, Nature Reviews Immunology.

[41]  V. Govorun,et al.  [Analysis of point mutations in the ygeD, gyrA and parC genes in fluoroquinolones resistant clinical isolates of Chlamydia trachomatis]. , 2004, Molekuliarnaia genetika, mikrobiologiia i virusologiia.

[42]  G. Zhong,et al.  Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Richard S. Stephens,et al.  Global Stage-Specific Gene Regulation during the Developmental Cycle of Chlamydia trachomatis , 2003, Journal of bacteriology.

[44]  W. Stamm,et al.  Methodologies and Cell Lines Used for Antimicrobial Susceptibility Testing of Chlamydia spp , 2003, Antimicrobial Agents and Chemotherapy.

[45]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[46]  T. Hackstadt,et al.  Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle , 2000, Molecular microbiology.

[47]  Y. Shi,et al.  Identification and characterization of promoters regulating tuf expression in Chlamydia trachomatis serovar F. , 2000, Archives of biochemistry and biophysics.

[48]  T. Hatch,et al.  Characterization of In Vitro DNA Binding Sites of the EUO Protein of Chlamydia psittaci , 2000, Infection and Immunity.

[49]  R. W. Davis,et al.  Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. , 1998, Science.

[50]  D. Hooper.  Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  T. Hatch.  Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? , 1996, Journal of bacteriology.

[52]  T. Hackstadt,et al.  Hc1‐mediated effects on DNA structure: a potential regulator of chlamydial development , 1993, Molecular microbiology.

[53]  Z. Ziora,et al.  Quinolone antibiotics , 2019, MedChemComm.

[54]  R. Stephens,et al.  Developmental‐stage‐specific plasmid supercoiling in Chlamydia trachomatis , 1990, Molecular microbiology.

[55]  C. Smith,et al.  Chlamydia trachomatis. , 1989, New Jersey medicine : the journal of the Medical Society of New Jersey.

[56]  M. Gellert,et al.  Mechanistic aspects of DNA topoisomerases. , 1986, Advances in protein chemistry.

[57]  M. Gellert,et al.  Regulation of the genes for E. coli DNA gyrase: Homeostatic control of DNA supercoiling , 1983, Cell.

[58]  J. Wang,et al.  Interaction between DNA and an Escherichia coli protein omega. , 1971, Journal of molecular biology.